Abstract

PET/CT findings in gastric cancer: potential advantages and current limitations

Author(s): Saadet Atay-Rosenthal, Richard L Wahl and Elliot K Fishman

18F-fluorodeoxyglucose (18F-FDG) as a substrate for tumors with high glucose metabolism has been the most commonly used 18F-FDG-PET radiopharmaceutical in oncologic imaging. However, the usefulness of 18F-FDG-PET in gastric cancer has not yet been fully established. The intent of this review is to help to better understand the impact of 18F‑FDG-PET on the imaging of gastric cancer, to offer a greater understanding of how gastric malignancies may present and be recognized on 18F‑FDG‑PET and to assess the complementary value of PET/CT in gastric cancer staging.